MYC and neoplasm: These results demonstrate that trametinib effectively inhibited tumor growth, enhanced the DNA damage response, and induced apoptosis in both JHU22-LV and JHU22-MYC xenograft tumors, with more pronounced effects in MYC-overexpressing tumors.